KRYS
Krystal Biotech, Inc. · Healthcare · Biotechnology
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 1 | 0 | 1.33K | $436,744 | n/a | −1 |
| Q2 2026 | 107 | +2 | 18.97M | $7.05B | +12 | −11 |
| Q1 2026 | 109 | 0 | 17.81M | $4.60B | +7 | −8 |
| Q4 2025 | 109 | +2 | 19.84M | $4.89B | +3 | n/a |
| Q3 2025 | 18 | +1 | 16.09M | $2.84B | +2 | −2 |
| Q2 2025 | 15 | -1 | 14.75M | $2.03B | n/a | −1 |
| Q1 2025 | 13 | +1 | 3.64M | $657.03M | +1 | n/a |
| Q4 2024 | 12 | +1 | 3.56M | $557.49M | +1 | n/a |
| Q3 2024 | 10 | +2 | 2.25M | $408.78M | +2 | n/a |
| Q2 2024 | 8 | n/a | 2.10M | $386.05M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Capital World Investors ✦ | 878.16K | n/a | $161.26M | 0.0% | n/c | 1 | SEC ↗ |
| 2 | T. Rowe Price ✦ | 600.14K | n/a | $110.21M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 3 | Geode Capital Management ✦ (passive) | 580.22K | n/a | $106.57M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 4 | Norges Bank ✦ (passive) | 11.34K | n/a | $2.08M | 0.0% | n/c | 1 | SEC ↗ |
| 5 | D. E. Shaw & Co. ✦ | 11.05K | n/a | $2.03M | 0.0% | n/c | 1 | SEC ↗ |
| 6 | Wellington Management ✦ | 11.02K | n/a | $2.02M | 0.0% | n/c | 1 | SEC ↗ ×4 |
| 7 | AQR Capital Management ✦ | 7.59K | n/a | $1.39M | 0.0% | n/c | 1 | SEC ↗ |
| 8 | Millennium Management ✦ | 2.57K | n/a | $471,955 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 364 holders, 28.19M shares, $7.07B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer, Director, 10% owner · 399 sh · $146,256
Officer, Director, 10% owner · 3.96K sh · $1.42M
Officer, Director, 10% owner · 3.18K sh · $1.14M
Officer, Director, 10% owner · 3.39K sh · $1.22M
Officer, Director, 10% owner · 2.32K sh · $836,281
Officer, Director, 10% owner · 1.24K sh · $449,120
Officer, Director, 10% owner · 1.99K sh · $722,404
Officer, Director, 10% owner · 565 sh · $205,287
Officer, Director, 10% owner · 1.33K sh · $484,390
Officer, Director, 10% owner · 826 sh · $301,832
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology